Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Beijing Friendship Hospital, Capital Medical University, Beijing

Liaoning Cancer Hospital and Institute, Shenyang

The First Hospital of Jilin University, Changchun

Harbin Medical University Cancer Hospital, Harbin

Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei

Institute of Hematology and Hospital of Blood Disease, Tianjin

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou

Taizhou Hospital of Zhejiang, Taizhou

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

Fujian Cancer Hospital, Fuzhou

The Second Xiangya Hospital of Central South University, Changsha

Hunan Cancer Hospital, Changsha

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

Henan Cancer Hospital, Zhengzhou

Sun Yat Sen University Cancer Center, Guangzhou

Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

The First Affiliated Hospital of Shantou University Medical College, Shantou

Hainan Cancer Hospital, Haikou

West China Hospital, Sichuan University, Chengdu

Yunnan Cancer Hospital, Kunming

Shanxi Provincial Cancer Hospital, Taiyuan